A new report from Evaluate Vantage looks at recent developments in gene editing and delivery.
Important ovarian cancer data are ahead for Immunogen and Mersana, while Disc Medicine eyes a rare metabolic disorder.
Will biotech lead a bull market recovery? Will Novartis spin off its cell therapy business? Read on for some of your leftfield predictions for biopharma.
Sangamo emulates Editas, while Crispr/Vertex and Bluebird add weight to their ambitions.
Data on the group’s sickle cell project do not feature in the regular abstracts, while Bluebird walks away from its short hairpin contender.